Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 7, 2026
Avenue Therapeutics, Inc. (ATXI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $690,000.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-690,000
-306.0% vs year-ago quarter
Operating cash flow
$-475,000
-169.9% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
3.29M
+3.5% vs year-ago quarter
Net cash
—
Operating margin
21.2%
Q2 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATXI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bay Harbor Islands, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1644963
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 | $1.4M |
| Operating income | -$707,000 | -$714,000 | -$752,000 | -$724,000 | $297,000 |
| Net income | -$690,000 | -$695,000 | -$709,000 | -$683,000 | $335,000 |
| Operating cash flow | -$475,000 | -$438,000 | -$854,000 | $383,000 | -$176,000 |
| Total assets | $2.0M | $2.5M | $2.9M | $3.7M | $4.2M |
| Total liabilities | $1.4M | $1.3M | $1.1M | $1.4M | $1.3M |
| Stockholders' equity | $569,000 | $1.2M | $1.8M | $3.6M | $4.1M |
| Cash and investments | $1.9M | $2.4M | $2.9M | $3.7M | $3.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 23, 2026 | Feb 18, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Dec 31, 2025 | Dec 30, 2025 |
| 8-K |
Current report
Other events
|
Nov 18, 2025 | Nov 14, 2025 |
All 423 Avenue Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.